Payment overview · 2025
General Payments
$582.43
37 reported records · 9 companies
Healthcare provider profile · identity verified
Mark A Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1033114988
Verified facts
What the public records show
CMS Open Payments records show Mark A Williams, MD received $582.43 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.17 | 24.1% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.20 | 23.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.60 | 19.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.99 | 10.6% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $37.59 | 6.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.27 | 6.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.67 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.92 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.02 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $582.43 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.92 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.92 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $74.27 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.17 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.00 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.55 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.61 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| SCOPIS ENT Normalized: scopis ent |
Device | Stryker Corporation | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| AUDION ET DILATION SYSTEM Normalized: audion et dilation system |
Device | Stryker Corporation | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 152 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
152 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 679 | 151 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 582 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 131 |
| Alprazolam | Alprazolam | 474 | 65 |
| Losartan Potassium | Losartan Potassium | 409 | 105 |
| Lisinopril | Lisinopril | 406 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 111 |
| Furosemide | Furosemide | 380 | 106 |
| Gabapentin | Gabapentin | 369 | 69 |
| Potassium Chloride | Potassium Chloride | 367 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 362 | 51 |
| Omeprazole | Omeprazole | 348 | 86 |
| Meloxicam | Meloxicam | 319 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 85 |
| Metformin Hcl | Metformin Hcl | 292 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 63 |
| Lorazepam | Lorazepam | 235 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 215 | 52 |
| Tramadol Hcl | Tramadol Hcl | 212 | 40 |
| Trazodone Hcl | Trazodone Hcl | 207 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 43 |
| Glimepiride | Glimepiride | 172 | 50 |
| Montelukast Sodium | Montelukast Sodium | 165 | 33 |
| Allopurinol | Allopurinol | 163 | 47 |
| Jardiance | Empagliflozin | 157 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 37 |
| Eliquis | Apixaban | 152 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 40 |
| Clonazepam | Clonazepam | 150 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 134 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 29 |
| Torsemide | Torsemide | 122 | 28 |
| Donepezil Hcl | Donepezil Hcl | 118 | 26 |
| Simvastatin | Simvastatin | 118 | 32 |
| Carvedilol | Carvedilol | 113 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 25 |
| Atenolol | Atenolol | 108 | 30 |
| Famotidine | Famotidine | 103 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 16 |
| Sertraline Hcl | Sertraline Hcl | 99 | 30 |
| Ozempic | Semaglutide | 93 | 19 |
| Warfarin Sodium | Warfarin Sodium | 92 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 26 |
| Mirtazapine | Mirtazapine | 90 | 27 |
| Alendronate Sodium | Alendronate Sodium | 86 | 22 |
| Metformin Hcl Er | Metformin Hcl | 86 | 29 |
| Spironolactone | Spironolactone | 84 | 21 |
| Celecoxib | Celecoxib | 83 | 24 |
| Buspirone Hcl | Buspirone Hcl | 81 | 16 |
| Farxiga | Dapagliflozin Propanediol | 77 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 18 |
| Irbesartan | Irbesartan | 74 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 18 |
| Pregabalin | Pregabalin | 73 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 16 |
| Ezetimibe | Ezetimibe | 67 | 17 |
| Finasteride | Finasteride | 67 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 17 |
| Synthroid | Levothyroxine Sodium | 63 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Cefdinir | Cefdinir | 59 | 48 |
| Fluconazole | Fluconazole | 59 | 34 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | suppressed |
| Methocarbamol | Methocarbamol | 56 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Cephalexin | Cephalexin | 54 | 44 |
| Methylprednisolone | Methylprednisolone | 51 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 42 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Clonidine Hcl | Clonidine Hcl | 49 | 16 |
| Linzess | Linaclotide | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 11 |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 12 |
| Colesevelam Hcl | Colesevelam Hcl | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 21 |
| Prednisone | Prednisone | 42 | 17 |
| Valsartan | Valsartan | 42 | 11 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 36 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 31 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Fosinopril Sodium | Fosinopril Sodium | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 17 |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lamictal Xr | Lamotrigine | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $582.43 · 37 records | ABBVIE INC. | AIRSUPRA, AREXVY, AUDION ET DILATION SYSTEM, BREZTRI, CREON, ELIQUIS, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SCOPIS ENT, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error